title: Pediatric urinary tract infections: the role of fluoroquinolones.
abstract: Infections of the urinary tract (UTI) occur commonly in the pediatric population. Because of the high association of pediatric UTI with congenital structural anomalies of the urinary tract and with dysfunctional elimination syndromes, it is far more common for children to be categorized as having complicated UTI than their adult counterparts. And for children more intensive therapy is often required. Early and effective treatment of UTIs in the pediatric patient is considered essential to prevent long term morbidity and potential mortality from end stage renal disease. An oral antimicrobial is more convenient than parenteral therapy and is preferable as long as clinical efficacy and safety can be assured. Oral fluoroquinolones are an attractive alternative for the treatment of complicated UTI in children, and safety must always be a factor in considering their use in this population. Although the role of fluoroquinolones in pediatric UTI is still under investigation, the limited data available demonstrate a likelihood of efficacy and safety.
authors.affiliation: Department of Pediatric Urology, The Children's Hospital, Denver, CO 80218, USA. marty.koyle@uchsc.edu
authors.forename: Martin A
authors.initials: MA
authors.lastname: Koyle
authors.forename: Albaha
authors.initials: A
authors.lastname: Barqawi
authors.forename: Jodi
authors.initials: J
authors.lastname: Wild
authors.forename: Michelle
authors.initials: M
authors.lastname: Passamaneck
authors.forename: Peter D
authors.initials: PD
authors.lastname: Furness
mesh_terms: D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009643:Norfloxacin / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology*
chemical_list: D024841:Fluoroquinolones; D002939:Ciprofloxacin; D009643:Norfloxacin